This segment focuses on the research, development, and manufacturing of therapeutic peptide APIs and finished dosage forms. Hybio utilizes advanced peptide synthesis and purification technologies to produce a range of products, including liraglutide, semaglutide, and exenatide for diabetes treatment, as well as products for digestive health and obstetrics/gynecology. The company's manufacturing processes adhere to GMP standards, meeting both EU and FDA requirements. This segment aims to improve patient outcomes by providing high-quality, effective peptide-based medications. Future growth will be driven by expanding the product portfolio, increasing production capacity, and entering new markets. Regulatory compliance and clinical validation are critical aspects of this segment.

Hybio offers comprehensive Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) services to support the development of peptide APIs and finished dosage forms. These services include process development, formulation development, reference standard preparation, impurity and product quality analysis, and regulatory support. The company's CDMO platform is designed to assist clients throughout the drug development lifecycle, from early-stage research to commercial manufacturing. This segment leverages advanced analytical techniques and quality control measures to ensure the safety and efficacy of peptide-based therapeutics. The focus is on providing customized solutions and accelerating the drug development process for partners. Future opportunities include expanding service offerings and establishing strategic partnerships to enhance market access and accelerate product launches.

This segment concentrates on the development and commercialization of peptide-based drugs for diabetes and metabolic disorders. Hybio's key products in this area include liraglutide, semaglutide, and exenatide, which are GLP-1 receptor agonists used to treat type 2 diabetes. The company is actively involved in research and development to improve the efficacy and delivery of these medications. This segment addresses a significant unmet medical need, as diabetes is a growing global health concern. Hybio's market positioning is strengthened by its focus on high-quality peptide manufacturing and its ability to provide comprehensive services. Future growth will be driven by expanding the product pipeline, securing regulatory approvals in key markets, and establishing strategic partnerships to enhance market access.